Dennis Goldberg, PhD

Chief Executive Officer, Director.

Dr. Goldberg has more than 30 years of experience in the pharmaceutical and biotechnology industries, ranging from drug discovery at a Fortune 25 company to chief executive officer of several biotechnology companies, including LipimetiX Development, Transport Pharmaceuticals, BZL Biologics and Talaria Therapeutics.  BZL’s antibody technology was licensed by Millennium Pharmaceuticals (NASDAQ:MLNM) and Talaria was acquired by Esperion Therapeutics (NASDAQ:ESPR). Dr. Goldberg was also Vice President of Product Development and Regulatory Affairs at GelTex Pharmaceuticals (NASDAQ:GELX), where he was responsible for all biological and clinical development activities, leading to the approval of RenaGel® and WelChol®. Dr. Goldberg holds a Ph.D. in Physiology and Biochemistry from Temple University and received post-doctoral training at the University of Pennsylvania and at the Specialized Center of Research on Atherosclerosis, University of California, San Diego. He is a Fellow of the American Heart Association.

%d bloggers like this: